China’s NHSA Publishes Preliminary List for 2025 National Reimbursement Drug List and Commercial Insurance Innovative Drug List
China’s National Healthcare Security Administration (NHSA) released the preliminary formal review results for the 2025...
Legend Biotech Reports Q2 Revenue Growth of 36.7% and H1 Growth of 60.4%
China-based Legend Biotech Corporation (NASDAQ: LEGN) reported unaudited financial statements for the three months (Q2)...
Takeda Reports Q1 FY2025 Revenue Dip Led by FX Headwinds and Generic Competition
Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) reported financial results for the first quarter of...
Hengrui’s Trastuzumab Rezetecan and Adebrelimab Granted Breakthrough Therapy Designation by China’s NMPA
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HKG: 1276, SHA: 600276) announced on August 11, 2025,...
Macao Drug Administration Expands White List for Designated Medical Institutions in Cooperation Zone
The Drug Administration of the Macao Special Administrative Region (SAR) of China has announced the...
CureVac and GSK Resolve mRNA Vaccine Patent Dispute With BioNTech and Pfizer
CureVac N.V. (NASDAQ: CVAC) announced on August 7, 2025, that it has reached an agreement...
Shanghai Moyang Biotechnology Secures Hundreds of Millions in Funding to Expand Global Reach
Shanghai Moyang Biotechnology Co., Ltd. announced on August 8, 2025, that it has successfully closed...
Novartis Begins Shipping Next-Gen Anti-VEGF Drug Beovu for Diabetic Macular Edema
Swiss pharmaceutical giant Novartis (NYSE: NVS) announced on August 11, 2025, the initiation of commercial...
Arvinas and Pfizer’s Vepdegestrant NDA Accepted by FDA for ER+/HER2- Breast Cancer
Arvinas, Inc. (NASDAQ: ARVN) and its partner Pfizer (NYSE: PFE) announced on August 8, 2025,...
J&J MedTech Gains China Approval for MENTOR MemoryGel Xtra Breast Implants
US major Johnson & Johnson MedTech announced that its MENTOR MemoryGel Xtra Breast Implants have...
Mabwell Initiates U.S. Clinical Study of 9MW2821 for Triple-Negative Breast Cancer
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced the first patient dosing in the...
Fosun Pharma Inks Licensing Pact With Expedition for DPP-1 Inhibitor XH-S004
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced on August 11, 2025, that...
Huadong Medicine Inks Exclusive Deal for JAK1 Inhibitor VC005 in China
On August 12, 2025, China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its exclusive...
Biocytogen Partners with Megarobo to Drive Intelligent Upgrading in Antibody R&D
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has entered into a...
Merck KGaA Reports Q2 Results Amid Currency Headwinds and SpringWorks Acquisition
Germany-based multinational Merck KGaA (ETR: MRK) reported Q2 2025 financial results, which were significantly affected...
Akeso Announces Enrollment of First Patient in Ivonescimab Phase 3 Trial for Small Cell Lung Carcinoma
China-based Akeso Biopharma (HKG: 9926) announced that the first patient has been enrolled in the phase...
Junshi Biosciences’ Toripalimab Receives NMPA Acceptance for HER2-expressing UC Treatment
China’s Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) announced that it has received...
Shandong Boan’s Boyouping Receives NMPA Approval for Type 2 Diabetes Treatment
Shandong Boan Biotechnology Co., Ltd (HKG: 6955) announced on August 8, 2025, that its self-developed...
Boehringer Ingelheim’s HERNEXEOS Receives FDA Accelerated Approval for NSCLC Treatment
German pharmaceutical giant Boehringer Ingelheim (BI) announced that its HERNEXEOS (zongertinib tablets) has received accelerated...
Lepu Biopharma Signs Licensing Pact With Excalipoint for Preclinical Assets
China-based Lepu Biopharma Co., Ltd. (HKG: 2157) announced on August 1, 2025, that it has...